SUPN
What one share of Supernus Pharmaceuticals holds
Pharmaceutical Preparations
Supernus Pharmaceuticals, Inc. (the Company) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Supernus Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $14.56 |
|---|---|
| Profit | −$1.93 |
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | $0.33 |
| Cash and investments | $3.09 |
| Book value | $17.73 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $4.16 | $1.76 | $0.03 | $1.26 | — | $3.84 |
| 2017 | $5.67 | $1.07 | $0.04 | $2.11 | — | $5.21 |
| 2018 | $7.56 | $2.05 | $0.02 | $2.37 | — | $8.66 |
| 2019 | $7.30 | $2.10 | $0.05 | $2.61 | — | $11.33 |
| 2020 | $9.69 | $2.36 | $0.06 | $2.51 | — | $14.09 |
| 2021 | $10.67 | $0.98 | — | $2.34 | — | $15.32 |
| 2022 | $10.82 | $1.04 | $0.01 | $1.89 | — | $16.33 |
| 2023 | $10.95 | $0.02 | $0.01 | $1.99 | — | $16.84 |
| 2024 | $11.83 | $1.32 | $0.01 | $3.06 | — | $18.58 |
| 2025 | $12.74 | −$0.68 | $0.02 | $0.81 | — | $18.48 |